Debiopharm
 | |
| Société Anonyme | |
| Industry | biopharmaceutical |
| Founded | Lausanne, Switzerland (1979) |
| Founder | Dr Rolland-Yves Mauvernay |
| Headquarters | Lausanne, Switzerland |
Area served | Worldwide |
Key people |
|
| Products | |
| Owner | family-owned |
Number of employees | 350 |
| Slogan | We develop for patients |
| Website | www.debiopharm.com |
Debiopharm Group (Debiopharm) is a global biopharmaceutical group of companies headquartered in Lausanne, Switzerland. The group is family-owned and comprises Debiopharm International SA, Debiopharm Research & Manufacturing SA, Debiopharm Diagnostics SA, and its financial arms Debiopharm Investment SA.
The group in-licenses promising biologics and small molecules, develop them clinically and out-license them for commercialisation. It has developed triptorelin for the palliative treatment of advanced prostate cancer, endometriosis, uterine fibromyomas, precocious puberty, female infertility, breast cancer, ovarian cancer, and for the treatment of severe sexual deviations, as well as oxaliplatin for the treatment of colorectal cancer.
History
In 1979, Dr. Rolland-Yves Mauvernay founded Debiopharm Group. In 1981, the laboratory Cytotech was created in Martigny and a few years later became Debio R.P.. The company first worked on interferon and in 1982, started to focus on triptorelin after acquiring the rights to its development from Tulane University. The first license to market triptorelin was obtained in France, in 1986. In 1989, Debiopharm in-licensed oxaliplatin from Nagoya City University. The drug was first approved in Europe, in 1996. Debioclinic S.A. was founded in 1993. In September 2004, after having occupied various locations in Lausanne, Debiopharm Group moved its headquarters to its current situation. As of January 2016, the Debiopharm Group consists of about 350 employees.[1]
Structure
Debiopharm Group was founded in 1979 and is headquartered in Lausanne, Switzerland. The group consists of Debiopharm International SA, Debiopharm Research & Manufacturing SA, Debiopharm Diagnostics SA, and Debiopharm Investment SA.
Debiopharm Group has established alliances with several biotech, pharmaceutical and start-up companies as well as with academic institutions, including Sanofi-Aventis, Ipsen Pharma, Novartis, Curis, MSM Protein Technologies, Mercury Therapeutics, École Polytechnique Fédérale de Lausanne (EPFL).
Pipeline
The company has developed triptorelin under the brandnames Decapeptyl/Trelstar/Pamorelin for the palliative treatment of advanced prostate cancer, endometriosis, uterine fibromyomas, precocious puberty, female infertility, breast cancer and ovarian cancer, and under the brandnames Moapar/Salvacyl for the treatment of severe sexual deviations and of oxaliplatin (Eloxatin/Elplat) for the treatment of colorectal cancer.
Examples of drugs currently in clinical development:
- Debio 025 - Alisporivir (out-licensed to Novartis worldwide with the exception of Japan) - being developed for the treatment of hepatitis C virus (HCV) infection[2]
- Debio 0932 (in-licensed from Curis) - a small molecule inhibitor targeting Heat Shock Protein 90 (Hsp90) - expected to be registered for an oncology indication[3]
- Debio 0827 (in-licensed from Pharmaleads SAS) - being developed for the treatment of chronic pain conditions.[4]
Examples of projects in pre-clinical or earlier stages of development:
- Debio 0719 (in-licensed from Kirin Brewery Company Ltd.) - a molecule inhibitor of the lysophosphatidic acid (LPA) receptors - being developed for cancer treatment[5]
- Debio 0617 (in-licensed from Aurigene Discovery Technologies Ltd.) is being researched for the treatment of cancer[6]
- Debio 0930 (in-licensed from Mercury Therapeutics, Inc.) - a small molecule activator of adenosine monophosphate-activated protein kinase (AMPK) for the treatment of type 2 diabetes[7]
- Debio 0826 (co-developed with the EPFL)- a program aimed at the identification of novel small molecules and peptides that have anti-tumoral, anti-metastatic and anti-angiogenic properties and fight cancer stem cells[8]
- Debio 0929 (co-developed with MSM Protein Technologies - an antibody targeting a G protein-coupled receptor (GPCR) to be developed into a new oncology therapeutic drug[9]
Awards
- 2011: Debiopharm Group heads the HR ranking of the Bilan Magazine, SME category
- 2010: Debiopharm Group was awarded the “Frost & Sullivan European Biopharmaceuticals Company of the Year Award”[10]
- 2004: Eloxatin was awarded the Prix Galien
Sponsorship
Debiopharm Group has funded a chair at the École polytechnique fédérale de Lausanne (EPFL),[11] and sponsors three scientific awards; the Debiopharm Life Sciences Award (EPFL, Lausanne, Switzerland); the JCA (Japanese Cancer Association)-Mauvernay Award and the Debiopharm / Valais Life Sciences Award in Valais, Switzerland.
Notes and references
- ↑ "Debiopharm Group - At a glance". Retrieved 16 February 2016.
- ↑ Crabbé R et al., An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opin Investig Drugs. 2009 Feb;18(2):211-20..
- ↑ Press release: Debiopharm Group starts Phase I clinical trial with Debio 0932.
- ↑ Press release: Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions.
- ↑ Press release: Debiopharm signs R&D and Commercialisation Agreement with Kirin for the development of Debio-0719 in Oncology
- ↑ Press release: Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
- ↑ Press release: Debiopharm Group and Mercury Therapeutics, Inc. sign an exclusive license agreement for the development and commercialisation of Debio 0930 - A first-in-class, small molecule activator of AMPK for treatment of type 2 diabetes.
- ↑ Press release: Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate For Cancer Treatment.
- ↑ Press release: Debiopharm and MSM Protein Technologies sign agreement for Research and Development of Debio 0929, a Novel Oncology Biologic.
- ↑ Press release: Frost & Sullivan Confers European Biopharmaceuticals Company of the Year Award on Debiopharm Group.
- ↑ Press release: EPFL and Debiopharm take on cancer metastasis with a new Chair.
See also
External links
 |
Wikimedia Commons has media related to Debiopharm. |
Coordinates: 46°30′54″N 6°38′28″E / 46.51500°N 6.64111°E